124 related articles for article (PubMed ID: 11395308)
1. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.
Bonasera TA; Ortu G; Rozen Y; Krais R; Freedman NM; Chisin R; Gazit A; Levitzki A; Mishani E
Nucl Med Biol; 2001 May; 28(4):359-74. PubMed ID: 11395308
[TBL] [Abstract][Full Text] [Related]
2. A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.
Hirata M; Kanai Y; Naka S; Yoshimoto M; Kagawa S; Matsumuro K; Katsuma H; Yamaguchi H; Magata Y; Ohmomo Y
Ann Nucl Med; 2013 Jun; 27(5):431-43. PubMed ID: 23494210
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of novel
Chong Y; Chang J; Zhao W; He Y; Li Y; Zhang H; Qi C
J Labelled Comp Radiopharm; 2018 Feb; 61(2):42-53. PubMed ID: 28833405
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.
Su H; Seimbille Y; Ferl GZ; Bodenstein C; Fueger B; Kim KJ; Hsu YT; Dubinett SM; Phelps ME; Czernin J; Weber WA
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1089-99. PubMed ID: 18239919
[TBL] [Abstract][Full Text] [Related]
5. Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes.
Vasdev N; Dorff PN; O'Neil JP; Chin FT; Hanrahan S; VanBrocklin HF
Bioorg Med Chem; 2011 May; 19(9):2959-65. PubMed ID: 21478021
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of EGFR-TK Expression with a
Si Z; Hu P; Zhou J; Lin Q; Xiu Y; Cheng D
Cancer Biother Radiopharm; 2019 Nov; 34(9):551-558. PubMed ID: 31436470
[No Abstract] [Full Text] [Related]
7. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
Neto C; Fernandes C; Oliveira MC; Gano L; Mendes F; Kniess T; Santos I
Nucl Med Biol; 2012 Feb; 39(2):247-60. PubMed ID: 22079040
[TBL] [Abstract][Full Text] [Related]
8. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E
Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization and evaluation of
Liolios C; Shegani A; Roupa I; Kiritsis C; Makarem A; Paravatou-Petsotas M; Pelecanou M; Bouziotis P; Papadopoulos M; Kopka K; Pirmettis I
Bioorg Chem; 2020 Jul; 100():103855. PubMed ID: 32428743
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.
Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
Ann Nucl Med; 2012 Jun; 26(5):381-9. PubMed ID: 22354330
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
13. Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.
Slobbe P; Windhorst AD; Stigter-van Walsum M; Schuit RC; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ
Nucl Med Biol; 2014 Oct; 41(9):749-57. PubMed ID: 25066021
[TBL] [Abstract][Full Text] [Related]
14. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.
Ben-David I; Rozen Y; Ortu G; Mishani E
Appl Radiat Isot; 2003 Feb; 58(2):209-17. PubMed ID: 12573320
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
Ann Nucl Med; 2011 Feb; 25(2):117-24. PubMed ID: 21058048
[TBL] [Abstract][Full Text] [Related]
16. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
Tsou HR; Mamuya N; Johnson BD; Reich MF; Gruber BC; Ye F; Nilakantan R; Shen R; Discafani C; DeBlanc R; Davis R; Koehn FE; Greenberger LM; Wang YF; Wissner A
J Med Chem; 2001 Aug; 44(17):2719-34. PubMed ID: 11495584
[TBL] [Abstract][Full Text] [Related]
17. Radiosynthesis and biological evaluation of
Huang S; Han Y; Chen M; Hu K; Qi Y; Sun P; Wang M; Wu H; Li G; Wang Q; Du Z; Zhang K; Zhao S; Zheng X
Bioorg Med Chem Lett; 2018 Apr; 28(6):1143-1148. PubMed ID: 29486966
[TBL] [Abstract][Full Text] [Related]
18. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
[TBL] [Abstract][Full Text] [Related]
19. Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a 99mTc biomarker for EGFR-TK imaging.
Fernandes C; Santos IC; Santos I; Pietzsch HJ; Kunstler JU; Kraus W; Rey A; Margaritis N; Bourkoula A; Chiotellis A; Paravatou-Petsotas M; Pirmettis I
Dalton Trans; 2008 Jun; (24):3215-25. PubMed ID: 18688420
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
